New York, New York-- (Newsfile Corp. - December 3, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...

THE LAWSUIT: A class action securities lawsuit was filed against Humacyte, Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between May 10, ...

The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the U.S. District Court for the North Carolina Middle District on behalf of those who acquired ...

Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, today announced that Laura Niklason, ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has be ...

On Friday, Humacyte Inc (HUMA) stock saw a modest uptick, ending the day at $4.47 which represents a slight increase of $0.07 or 1.59% from the prior close of $4.4. The stock opened at $4.44 and ...

If you suffered losses exceeding $75,000 in Humacyte between May 10, 2024 and October 17, 2024 and would like to discuss your ...

Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

DURHAM, N.C., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...

On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.45 which represents a decrease of $-0.07 or -1.55% from the prior close of $4.52. The stock opened at $4.56 and touched a low ...

New York, New York--(Newsfile Corp. - November 25, 2024) - Faruqi & Faruqi, LLP, a leading national securities law firm, is ...